These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 18050221

  • 1. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F.
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [Abstract] [Full Text] [Related]

  • 2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
    Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A.
    J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM.
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group.
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [Abstract] [Full Text] [Related]

  • 6. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.
    Thurlings RM, Vos K, Gerlag DM, Tak PP.
    Arthritis Rheum; 2008 Dec; 58(12):3657-64. PubMed ID: 19035505
    [Abstract] [Full Text] [Related]

  • 7. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 8. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
    Sanmartí R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N, Rodriguez-Cros JR, Erra A, Reina D, Gratacós J.
    Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD.
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [Abstract] [Full Text] [Related]

  • 10. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 11. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.
    N Engl J Med; 2004 Jun 17; 350(25):2572-81. PubMed ID: 15201414
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B, Breedveld F.
    Arthritis Rheum; 2003 Jun 17; 48(6):1513-20. PubMed ID: 12794818
    [Abstract] [Full Text] [Related]

  • 14. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P.
    J Rheumatol; 2000 Apr 17; 27(4):841-50. PubMed ID: 10782805
    [Abstract] [Full Text] [Related]

  • 15. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct 17; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 16. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Oct 17; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP.
    Arthritis Rheum; 2009 Feb 17; 60(2):335-44. PubMed ID: 19180516
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.
    Arthritis Rheum; 2002 Aug 17; 46(8):2020-8. PubMed ID: 12209503
    [Abstract] [Full Text] [Related]

  • 19. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N, Gossec L, Dieudé P, Meyer O, Dougados M, Kahan A, Allanore Y.
    J Rheumatol; 2008 Jan 17; 35(1):31-4. PubMed ID: 18176989
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov 17; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.